Imeglimin

DRUG11 trials

Conditions

BioequivalenceDiabetes Mellitus, Type 2HealthyHepatic ImpairmentMetforminMitochondriaQt Interval, Variation inType 2 Diabetes Mellitus

Phase 1

Safety, Tolerability and PK of Imeglimin in Japanese Volunteers

CompletedNCT02373150

Poxel SAType 2 Diabetes Mellitus

Start: 2015-02-28End: 2015-10-31Updated: 2017-02-10

Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects

CompletedNCT02924337

Poxel SAQt Interval, Variation in

Start: 2016-09-30End: 2016-12-31Updated: 2017-02-10

Effect of Cimetidine on the PK of Imeglimin

CompletedNCT03618316

Poxel SAHealthy

Start: 2018-06-19End: 2018-07-27Updated: 2018-08-27

Bioequivalence of Imeglimin Tablet Formulations

CompletedNCT03646331

Poxel SABioequivalence

Start: 2018-09-03End: 2018-10-02Updated: 2019-01-11

Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects

CompletedNCT03802786

Poxel SAHepatic Impairment

Start: 2018-11-06End: 2019-07-08Updated: 2020-08-11

Phase 2

A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes

CompletedNCT01951235

Poxel SAType 2 Diabetes Mellitus

Start: 2013-01-31End: 2014-07-31Updated: 2015-08-13

A study investigating the effects of metformin and imeglimin on metal balance in patients with type 2 diabetes

RecruitingJPRN-jRCTs051260018

Sakaguchi Kazuhikotype 2 diabetes diabetes

Start: 2026-04-10Target: 64Updated: 2026-06-29

Phase 4

Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus

Active, not recruitingNCT05366868

National Center for Global Health and Medicine, JapanDiabetes Mellitus, Type 2

Start: 2022-05-26End: 2027-03-31Target: 567Updated: 2026-04-09

Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy

Not yet recruitingNCT07436182

Mansoura UniversityMetformin, Mitochondria

Start: 2026-03-01End: 2026-06-01Target: 176Updated: 2026-02-27

Unknown Phase

Effect of Imeglimin on muscle sympathetic nerve activiy in type 2 diabetes mellitus patients

RecruitingJPRN-jRCT1041220023

Takamura MasayukiType 2 diabetes Type 2 diabetes, muscle sympathetic nerve activity

Start: 2022-05-28Target: 30Updated: 2026-06-29

Comparative evaluation of clinical markers indicating hypoglycaemia treated with ImeglimiN and its eFfect on erythrocytes IN patIents with TYpe 2 diabetes

Active, not recruitingJPRN-jRCTs031220489

Osonoi TakeshiType 2 diabetes mellitus Type 2 diabetes mellitus

Start: 2022-12-05Target: 30Updated: 2026-06-29

Related Papers

Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial.

2025-10-24

Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial

Frontiers in Pharmacology2023-06-072 citations

Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.

2020-06-1811 citations